Polaris Group 6550
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- TWD 54.80
- Day Range
- TWD 54.70–56.30
- 52-Week Range
- TWD 51.80–81.90
- Bid/Ask
- TWD 55.10 / TWD 55.20
- Market Cap
- TWD 41.16 Bil
- Volume/Avg
- 632,041 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 625.56
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- —
- Website
- https://www.polarispharma.com
Comparables
Valuation
|
Metric
|
6550
|
IMU
|
02105
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 8.85 |
Price/Book Value | 5.94 | 3.03 | 3.00 |
Price/Sales | 625.56 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
6550
IMU
02105
Financial Strength
|
Metric
|
6550
|
IMU
|
02105
|
|---|---|---|---|
Quick Ratio | 9.39 | 3.66 | 5.00 |
Current Ratio | 9.86 | 3.86 | 5.07 |
Interest Coverage | −41.75 | −321.34 | −140.41 |
Quick Ratio
6550
IMU
02105
Profitability
|
Metric
|
6550
|
IMU
|
02105
|
|---|---|---|---|
Return on Assets (Normalized) | −18.61% | −67.09% | −30.40% |
Return on Equity (Normalized) | −22.52% | −77.26% | −34.99% |
Return on Invested Capital (Normalized) | −21.09% | −79.58% | −35.28% |
Return on Assets
6550
IMU
02105
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hnlfzwpb | Frdt | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lzxdnmq | Zbwsnx | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cdtnwwxmd | Bsqxtcg | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Clwqswkr | Nzcdf | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Zzwswbmnr | Cmpy | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Tlbwchc | Rrrf | $28.1 Bil | |||
| Moderna Inc
MRNA
| Hnknxzwq | Wzff | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Vmsnlwqjh | Vwh | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gzmlckqy | Jfmczrz | $13.4 Bil | |||
| Incyte Corp
INCY
| Lvtlfvvxz | Xgzyn | $12.7 Bil |
United States